文献
J-GLOBAL ID:201802241334935492
整理番号:18A0492185
アルツハイマー病精神病患者におけるピマバンセリン対プラセボの安全性,忍容性,および有効性の評価:第2相,無作為化,プラセボ対照二重盲検試験【Powered by NICT】
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
著者 (9件):
Ballard Clive
(Institute of Health Research, University of Exeter Medical School, Exeter, UK)
,
Banister Carol
(Wolfson Centre for Age-related Diseases, King’s College London, London, UK)
,
Khan Zunera
(Wolfson Centre for Age-related Diseases, King’s College London, London, UK)
,
Cummings Jeffrey
(Department Center for Brain Health, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA)
,
Demos George
(ACADIA Pharmaceuticals, San Diego, CA, USA)
,
Coate Bruce
(ACADIA Pharmaceuticals, San Diego, CA, USA)
,
Youakim James M
(ACADIA Pharmaceuticals, San Diego, CA, USA)
,
Owen Randall
(ACADIA Pharmaceuticals, San Diego, CA, USA)
,
Stankovic Srdjan
(ACADIA Pharmaceuticals, San Diego, CA, USA)
資料名:
Lancet Neurology
(Lancet Neurology)
巻:
17
号:
3
ページ:
213-222
発行年:
2018年
JST資料番号:
W3105A
ISSN:
1474-4422
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)